Document Detail

Pixantrone maleate for non-Hodgkin's lymphoma.
MedLine Citation:
PMID:  20126672     Owner:  NLM     Status:  MEDLINE    
Pixantrone (BBR-2778) is a novel aza-anthracenedione anthracycline derivative developed by Cell Therapeutics Incorporated, WA, USA. Pixantrone is similar in structure to the anthracenedione mitoxantrone but lacks the 5, 8-dihydroxy substitution groups implicated in mitoxantrone-induced cardiotoxicity. The PIX301 phase III single-agent trial of pixantrone for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma randomized patients to receive either pixantrone or another single agent of the investigators' choice. The rate of confirmed and unconfirmed remissions in patients treated with pixantrone was significantly higher than in those receiving other agents, as was the overall response rate and progression-free survival. There is evidence that pixantrone is well tolerated when substituted for anthracyclines in combination regimens for aggressive non-Hodgkin's lymphoma with comparable rates of complete remission. Pixantrone has also been used for the treatment of indolent non-Hodgkin's lymphomas and the combination of pixantrone and rituximab has been shown to be superior to rituximab alone in relapsed or refractory disease in the phase III PIX302 study. On the basis of these data, the United States Food and Drug Administration is considering pixantrone for use in adult patients with relapsed or refractory aggressive and indolent non-Hodgkin's lymphoma on a fast-track basis.
Deborah Mukherji; Ruth Pettengell
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drugs of today (Barcelona, Spain : 1998)     Volume:  45     ISSN:  1699-3993     ISO Abbreviation:  Drugs Today     Publication Date:  2009 Nov 
Date Detail:
Created Date:  2010-02-03     Completed Date:  2010-04-27     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101160518     Medline TA:  Drugs Today (Barc)     Country:  Spain    
Other Details:
Languages:  eng     Pagination:  797-805     Citation Subset:  IM    
Copyright Information:
Copyright 2009 Prous Science, S.A.U. or its licensors. All rights reserved.
Medical Oncology, St. Georges Hospital, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / adverse effects,  pharmacology,  therapeutic use*
Clinical Trials as Topic
DNA Topoisomerases, Type II / antagonists & inhibitors
Drug Evaluation, Preclinical
Isoquinolines / adverse effects,  pharmacology,  therapeutic use*
Lymphoma, Non-Hodgkin / drug therapy*,  physiopathology
Reg. No./Substance:
0/Antineoplastic Agents; 0/Isoquinolines; 144510-96-3/pixantrone; EC Topoisomerases, Type II

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Romidepsin for the treatment of cutaneous T-cell lymphoma.
Next Document:  Recent advances in the pharmacological treatment of cardiac arrythmias.